Traders should monitor upcoming 2026 catalysts, particularly EMA decisions on OJEMDA and MIPLYFFA and Phase 3 data for ersodetug, which could drive further royalty upside. The company’s shift to positive operating cash flow and active buybacks support shareholder value, but litigation risk with Janssen remains a watch item.
Price Chart
Executive Summary
XOMA Royalty Corporation reported strong full-year 2025 financial results with revenue up 83% YoY to $52.1 million and a swing to net income of $31.7 million from a $13.8 million loss in 2024, driven by higher royalty and milestone receipts. The company repurchased $16.0 million in shares and expanded its portfolio with 22 new assets and seven acquisitions, while also securing potential future upside from late-stage pipeline catalysts in 2026.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue: $52.1 million (up 83% YoY from $28.5 million)
- Net income: $31.7 million in 2025 vs. net loss of $13.8 million in 2024
- Achieved $50.5 million in cash receipts: $33.6 million in royalties, $16.9 million in milestones
- Repurchased and retired 648,048 shares for $16.0 million in 2025
- Completed seven acquisitions, adding $11.7 million in non-dilutive capital and exposure to up to $1.1 billion in potential milestones
- Takeda deal expansion: up to $852.6 million in potential milestones and low to mid-single-digit royalties on nine assets
- Key 2026 catalysts: Phase 3 data for ersodetug in tumor HI, EMA decisions on OJEMDA and MIPLYFFA, and Phase 2b data for volixibat in PSC
Financial Impact
Revenue increased by $23.6 million YoY, with net income improving by $45.5 million. Operating cash flow turned positive at $2.9 million in 2025 vs. -$13.7 million in 2024.
Risk Factors
- Clinical setbacks in key pipeline assets (e.g., ersodetug failed to meet statistical significance in congenital HI)
- Ongoing litigation with Janssen Biotech with uncertain outcome and potential for continued legal costs
- Dependence on third-party drug development success and regulatory approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257974 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 14, 2026 11w ago | 8-K | $40.17 $40.17 | · 0.00% | ▲ +0.47% | $164.21 (+308.78%) |
Jun 12, 2026 15w ago | DEFA14A | $41.95 $42.00 | ▲ +0.12% | ▲ +1.50% | $164.21 (+291.43%) |
Jun 12, 2026 15w ago | 8-K | $41.95 $42.00 | ▲ +0.12% | ▲ +1.50% | $164.21 (+291.43%) |
Mar 18, 2026 28w ago | Press Release | $28.76 $30.53 | ▲ +6.15% | ▲ +8.37% | $164.21 (+470.95%) |
Mar 18, 2026 28w ago | 8-K | $27.35 $30.20 | ▲ +10.42% | ▲ +11.14% | $164.21 (+500.38%) |
Mar 18, 2026 28w ago | Press Release | $27.35 $30.20 | ▲ +10.42% | ▲ +11.14% | $164.21 (+500.38%) |
Mar 12, 2026 29w ago | Press Release | $26.86 $28.76 | ▲ +7.07% | ▲ +8.05% | $164.21 (+511.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access